Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Suicidal ideation with and without intention to act, A transdiagnostic network analysis on the interplay between psychopathology, impulsivity, and childhood maltreatment

  • De Prisco, Michele|||0000-0002-2032-1181
  • Roberto Herrero, Natalia|||0000-0002-5391-2711
  • Andreo Jover, Jorge|||0000-0002-6703-8017
  • Ayad-Ahmed, Wala|||0000-0002-0786-0076
  • Bobes-Bascarán, Maria T.|||0000-0002-5279-504X
  • Canal-Rivero, Manuel|||0000-0002-5818-5103
  • Canosa García, Irene
  • Cebrià, Ana Isabel|||0000-0002-2632-8130
  • Crespo-Facorro, Benedicto|||0000-0003-0033-7132
  • Curto-Ramos, Javier
  • Díaz-Marsá, Marina|||0000-0003-1364-3163
  • Torre-Luque, Alejandro de la|||0000-0003-0595-6127
  • Elices, M.|||0000-0002-7034-4242
  • Jiménez-Treviño, Luis|||0000-0002-9551-8587
  • Palao Tarrero, Ángela|||0000-0003-2717-5807
  • Palao, Diego|||0000-0002-3323-6568
  • Pemau, Andrés|||0000-0002-5835-507X
  • Lopez-Pena, Maria Purificacion
  • Ruiz Veguilla, Miguel
  • Sáiz, Pilar A.|||0000-0002-5705-4523
  • Suárez-Soto, Elizabeth|||0000-0001-7599-0078
  • Courtet, Philippe|||0000-0002-6519-8586
  • Vieta, Eduard|||0000-0002-0548-0053
  • Grande, Iria|||0000-0002-0137-0666
  • Pérez Solà, Víctor|||0000-0002-5825-2337
Suicide represents a significant public health concern. Suicide prevention strategies are shifting toward transdiagnostic perspectives examining interrelated risk factors, but their interrelationships remain unclear. This study investigated relationships between psychopathological dimensions, impulsivity, and childhood maltreatment in individuals with suicidal ideation (SI), comparing those with versus without intention to act using network analysis. Data were obtained from the Suicide Prevention and Intervention Study project. Participants were categorized into two groups based on their intention to act according to the Columbia Suicide Severity Rating Scale. Psychological symptoms, impulsivity traits, and childhood maltreatment were assessed. Network analysis was performed, and centrality measures were computed. A total of 1,265 individuals were categorized into the SI without intention to act (n = 345) and SI with intention to act (n = 920) groups. The former showed lower depression and hostility scores, and lower prevalence of major depressive and anxiety disorders. Network analyses revealed that in the SI without intention to act group, obsessive-compulsive symptoms were central, connecting to depression and anxiety, while negatively correlating with non-planning impulsivity. In contrast, the SI with intention to act group showed a more densely interconnected network where emotional abuse served as a bridge between childhood maltreatment and other psychopathological dimensions. This study identifies symptom interaction patterns between individuals with SI without and with intention to act. Understanding these relationships may improve suicide risk assessment and inform personalized interventions, potentially reducing the transition from ideation to action. Trauma-focused approaches addressing emotional abuse may be especially relevant for individuals at high risk.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Fine-mapping genomic loci refines bipolar disorder risk genes

  • Koromina, Maria|||0000-0001-8843-082X
  • Ravi, Ashvin
  • Panagiotaropoulou, Georgia
  • Schilder, Brian M.|||0000-0001-5949-2191
  • Humphrey, Jack
  • Braun, Alice|||0000-0003-1145-0261
  • Bigdeli, Tim B.|||0000-0003-2215-5946
  • Chatzinakos, Chris
  • Coombes, Brandon J.|||0000-0003-4322-5923
  • Kim, Jaeyoung|||0000-0001-6983-7907
  • Liu, Xiaoxi|||0000-0002-1933-8613
  • Terao, Chikashi|||0000-0002-6452-4095
  • O'Connell, Kevin S.|||0000-0002-6865-8795
  • Adams, Mark J
  • Adolfsson, Rolf
  • Alda, Martin|||0000-0001-9544-3944
  • Alfredsson, Lars|||0000-0003-1688-6697
  • Andlauer, Till F. M.|||0000-0002-2917-5889
  • Andreassen, Ole A.|||0000-0002-4461-3568
  • Antoniou, Anastasia
  • Baune, Bernhard T.|||0000-0001-6548-426X
  • Bengesser, Susanne
  • Biernacka, Joanna
  • Boehnke, Michael|||0000-0002-6442-7754
  • Bosch, Rosa|||0000-0002-7596-183X
  • Cairns, Murray J.
  • Carr, Vaughan J.
  • Casas Brugué, Miquel|||0000-0003-3496-8522
  • Catts, Stanley
  • Cichon, Sven|||0000-0002-9475-086X
  • Corvin, Aiden
  • Craddock, Nicholas
  • Dafnas, Konstantinos
  • Dalkner, Nina
  • Dannlowski, Udo|||0000-0002-0623-3759
  • Degenhardt, Franziska
  • Di Florio, Arianna
  • Dikeos, Dimitris
  • Fellendorf, Frederike Tabea
  • Ferentinos, Panagiotis|||0000-0001-8531-5623
  • Forstner, Andreas J.
  • Forty, Liz|||0000-0002-4349-8414
  • Frye, Mark
  • Fullerton, Janice M.|||0000-0003-4014-4490
  • Gawlik, Micha
  • Gizer, Ian R.
  • Gordon-Smith, Katherine
  • Green, Melissa J.
  • Grigoroiu-Serbanescu, Maria
  • Guzman-Parra, Jose|||0000-0002-1463-6435
  • Hahn, Tim|||0000-0002-8929-4134
  • Henskens, Frans
  • Hillert, Jan|||0000-0002-7386-6732
  • Jablensky, Assen V.
  • Jones, Lisa|||0000-0002-5122-8334
  • Jones, Ian
  • Jonsson, Lina
  • Kelsoe, John R.
  • Kircher, Tilo|||0000-0002-2514-2625
  • Kirov, George|||0000-0002-3427-3950
  • Kittel-Schneider, Sarah|||0000-0003-3057-6150
  • Kogevinas, Manolis|||0000-0002-9605-0461
  • Landén, Mikael|||0000-0002-4496-6451
  • Leboyer, Marion|||0000-0001-5473-3697
  • Lenger, Melanie
  • Lissowska, Jolanta
  • Lochner, Christine|||0000-0002-4766-3704
  • Loughland, Carmel
  • MacIntyre, Donald J.|||0000-0001-6963-1335
  • Martin, Nicholas G.|||0000-0003-4069-8020
  • Maratou, Eirini
  • Mathews, Carol A.|||0000-0003-2208-7058
  • Mayoral-Cleries, Fermín
  • McElroy, Susan L.
  • McGregor, Nathaniel|||0000-0001-7195-4993
  • McIntosh, Andrew M.|||0000-0002-0198-4588
  • McQuillin, Andrew|||0000-0003-1567-2240
  • Michie, Patricia|||0000-0002-4169-8519
  • Mitchell, Philip B.
  • Moutsatsou, Paraskevi
  • Mowry, Bryan J.|||0000-0002-4115-5645
  • Müller-Myhsok, Bertram
  • Myers, Richard M.
  • Nenadić, Igor|||0000-0002-0749-7473
  • Nievergelt, Caroline M.
  • Nöthen, Markus M.|||0000-0002-8770-2464
  • Nurnberger, John
  • O'Donovan, Michael C.|||0000-0001-7073-2379
  • 'Donovan, Claire O.
  • Ophoff, Roel A.
  • Owen, Michael J.
  • Pantelis, Christos|||0000-0002-9565-0238
  • Pato, Carlos|||0000-0002-5858-266X
  • Pato, Michele T.
  • Patrinos, George P.
  • Pawlak, Joanna M.
  • Perlis, Roy H.|||0000-0002-5862-6757
  • Porichi, Evgenia
  • Posthuma, Danielle|||0000-0001-7582-2365
  • Ramos-Quiroga, Josep Antoni|||0000-0003-1622-0350
  • Reif, Andreas|||0000-0002-0992-634X
  • Reininghaus, Eva Z.
  • Ribasés Haro, Marta|||0000-0003-1039-1116
  • Rietschel, Marcella|||0000-0002-5236-6149
  • Schall, Ulrich
  • Schofield, Peter R.|||0000-0003-2967-9662
  • Schulze, Thomas G.
  • Scott, Laura J.|||0000-0002-4886-5084
  • Scott, Rodney J.|||0000-0001-7724-3404
  • Serretti, Alessandro
  • Smoller, Jordan W.|||0000-0002-0381-6334
  • Świątkowska, Beata
  • Soler Artigas, María|||0000-0002-3213-1107
  • Stein, Dan J.|||0000-0001-7218-7810
  • Streit, Fabian|||0000-0003-1080-4339
  • Toma, Claudio|||0000-0003-3901-7507
  • Tooney, Paul
  • Vawter, Marquis P.
  • Vieta, Eduard|||0000-0002-0548-0053
  • Vincent, John B.
  • Waldman, Irwin D.|||0000-0002-6862-1837
  • Weickert, Cynthia Shannon
  • Weickert, Thomas
  • Witt, Stephanie H.|||0000-0002-1571-1468
  • Hong, Kyung Sue
  • Ikeda, Masashi|||0000-0001-6237-2449
  • Iwata, Nakao|||0000-0003-3189-6076
  • Won, Hong Hee
  • Edenberg, Howard J.|||0000-0003-0344-9690
  • Ripke, Stephan|||0000-0003-3622-835X
  • Raj, Towfique|||0000-0002-9355-5704
  • Coleman, Jonathan R.I.
  • Mullins, Niamh
Bipolar disorder is a heritable mental illness with complex etiology. While the largest published genome-wide association study identified 64 bipolar disorder risk loci, the causal SNPs and genes within these loci remain unknown. We applied a suite of statistical and functional fine-mapping methods to these loci and prioritized 17 likely causal SNPs for bipolar disorder. We mapped these SNPs to genes and investigated their likely functional consequences by integrating variant annotations, brain cell-type epigenomic annotations, brain quantitative trait loci and results from rare variant exome sequencing in bipolar disorder. Convergent lines of evidence supported the roles of genes involved in neurotransmission and neurodevelopment, including SCN2A, TRANK1, DCLK3, INSYN2B, SYNE1, THSD7A, CACNA1B, TUBBP5, FKBP2, RASGRP1, FURIN, FES, MED24 and THRA among others in bipolar disorder. These represent promising candidates for functional experiments to understand biological mechanisms and therapeutic potential. Additionally, we demonstrated that fine-mapping effect sizes can improve performance of bipolar disorder polygenic risk scores across diverse populations and present a high-throughput fine-mapping pipeline.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Safety intervention for improving functioning in suicidal attempters (STRONG): A secondary prevention study. Study rationale and research protocol

  • Roberto, Natalia
  • Toll, Alba
  • Elices, Matilde
  • Pérez Solà, Víctor
  • Grande, Iria
Data de publicació electrònica: 07-09-2023, Background: Suicide is one of the most largely preventable causes of death worldwide. The aim of the STRONG study is to assess the effectiveness of a specific intervention (an extended Safety Planning Intervention) called iFightDepression-SURVIVE (iFD-S) in suicidal attempters by changes in psychosocial functioning. As secondary outcomes, quality of life, cognitive performance, clinical state and neuroimaging correlates will be considered. Objective: To describe the rationale and design of the STRONG study, an extension of the SURVIVE study, a national multicenter cohort about on prevention in suicidal attempters. Methods: The STRONG study is a two-year clinical trial. A total sample of 60 patients will be randomly allocated to two arms: a group will receive a iFD-S and treatment as usual (TAU) (n=30 treatment group), while another group will exclusively receive TAU (n=30 control group). There will be three study points: baseline; 3-month; and 6-month follow-up assessments, all of which will include rater-blinded evaluation of psychosocial functioning, quality of life, clinical state, cognitive performance and neuroimaging acquisition. Results: It is expected to obtain data on the efficacy of iFD-S in patients who have committed a suicide attempt. Conclusion: Results will provide insight into the effectiveness of IFD-S in suicidal attempters with respect to improvements in psychosocial functioning, quality of life, cognition, and neuroimaging correlates. Clinical trials id: NCT05655390., EV wishes to acknowledge the support from CIBER – Consorcio Centro de Investigación Biomédica en Red – (CB07/09/0004), Instituto de Salud Carlos III, the Spanish Ministry of Science and Innovation (PI18/00805, PI21/00787), Instituto de Salud Carlos III – Fondo Europeo de Desarrollo Regional (FEDER). Unión Europea. “Una manera de hacer Europa”, cofinanciado por la Unión Europea; the CERCA Program/Generalitat de Catalunya and Secretaria d’Universitats i Recerca del Departament d’Economia I Coneixement (2021 SGR 01358). Departament de Salut de la Generalitat de Catalunya, Pla Estratègic de Recerca i Innovació en Salut (PERIS) 2016-2020 (SLT006/17/00357). Thanks are also given for the support received from the European Union Horizon 2020 research and innovation program (EU.3.1.1. Understanding health, wellbeing and disease: grant no. 754907 and EU.3.1.3. Treating and managing disease: grant no. 945151). ME has a Juan de la Cierva research contract awarded by the ISCIII (FJCI-2017-31738). VP, ME, and AT want to thank unrestricted research funding from “Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement” (2017 SGR 134 to “Mental Health Research Group”), Generalitat de Catalunya (Government of Catalonia). PAS has received partial support from the Government of the Principality of Asturias PCTI-2021-2023 IDI/2021/111, the Fundación para la Investigación e Innovación Biosanitaria del Principado de Asturias (FINBA), and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, and Ministerio de Ciencia e Innovación. The funders had no role in the study design, decision to publish, or preparation of the manuscript.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Association of polygenic score and the involvement of cholinergic and glutamatergic pathways with lithium treatment response in patients with bipolar disorder

  • Amare, Azmeraw T.
  • Colom, Francesc
  • Baune, Bernhard T.
Lithium is regarded as the first-line treatment for bipolar disorder (BD), a severe and disabling mental health disorder that affects about 1% of the population worldwide. Nevertheless, lithium is not consistently effective, with only 30% of patients showing a favorable response to treatment. To provide personalized treatment options for bipolar patients, it is essential to identify prediction biomarkers such as polygenic scores. In this study, we developed a polygenic score for lithium treatment response (Li+PGS) in patients with BD. To gain further insights into lithium's possible molecular mechanism of action, we performed a genome-wide gene-based analysis. Using polygenic score modeling, via methods incorporating Bayesian regression and continuous shrinkage priors, Li+PGS was developed in the International Consortium of Lithium Genetics cohort (ConLi+Gen: N = 2367) and replicated in the combined PsyCourse (N = 89) and BipoLife (N = 102) studies. The associations of Li+PGS and lithium treatment response - defined in a continuous ALDA scale and a categorical outcome (good response vs. poor response) were tested using regression models, each adjusted for the covariates: age, sex, and the first four genetic principal components. Statistical significance was determined at P < 0.05. Li+PGS was positively associated with lithium treatment response in the ConLi+Gen cohort, in both the categorical (P = 9.8 × 10-12, R2 = 1.9%) and continuous (P = 6.4 × 10-9, R2 = 2.6%) outcomes. Compared to bipolar patients in the 1st decile of the risk distribution, individuals in the 10th decile had 3.47-fold (95%CI: 2.22-5.47) higher odds of responding favorably to lithium. The results were replicated in the independent cohorts for the categorical treatment outcome (P = 3.9 × 10-4, R2 = 0.9%), but not for the continuous outcome (P = 0.13). Gene-based analyses revealed 36 candidate genes that are enriched in biological pathways controlled by glutamate and acetylcholine. Li+PGS may be useful in the development of pharmacogenomic testing strategies by enabling a classification of bipolar patients according to their response to treatment., AT Amare received the 2019–2021 National Alliance for Research on Schizophrenia and Depression (NARSAD) Young Investigator Grant from the Brain & Behaviour Research Foundation (BBRF) and is currently supported by National Health and Medical Research Council (NHMRC) Emerging Leadership (EL1) Investigator Grant (APP2008000). The primary sources of funding were the Deutsche Forschungsgemeinschaft (DFG; grant no.RI 908/7-1; grant FOR2107, RI 908/11-1 to Marcella Rietschel, NO 246/10-1 to Markus M. Nöthen) and the Intramural Research Program of the National Institute of Mental Health (ZIA-MH00284311; ClinicalTrials.gov identifier: NCT00001174). The genotyping was in part funded by the German Federal Ministry of Education and Research (BMBF) through the Integrated Network IntegraMent (Integrated Understanding of Causes and Mechanisms in Mental Disorders), under the auspices of the e:Med Programme (grants awarded to Thomas G. Schulze, Marcella Rietschel, and Markus M. Nöthen). Improving Recognition and Care in Critical Areas of Bipolar Disorders (BipoLife) study was funded by Bundesministerium für Bildung und Forschung (BMBF): PIs – Felix Bermpohl, Philipp Ritter, Michael Bauer, Andreas Reif, Sarah Kittel-Schneider, Thomas G. Schulze, Jens Wiltfang, Georg Juckel, Andreas Fallgatter and Martin Lambert. Urs Heilbronner was supported by European Union’s Horizon 2020 Research and Innovation Programme (PSY-PGx, grant agreement No 945151). Some data and biomaterials were collected as part of eleven projects (Study 40) that participated in the National Institute of Mental Health (NIMH) Bipolar Disorder Genetics Initiative. From 2003–2007, the Principal Investigators and Co-Investigators were: Indiana University, Indianapolis, IN, R01 MH59545, John Nurnberger, M.D., Ph.D., Marvin J. Miller, M.D., Elizabeth S. Bowman, M.D., N. Leela Rau, M.D., P.Ryan Moe, M.D., Nalini Samavedy, M.D., Rif El-Mallakh, M.D. (at University of Louisville), Husseini Manji, M.D.(at Johnson and Johnson), Debra A.Glitz, M.D.(at Wayne State University), Eric T.Meyer, Ph.D., M.S.(at Oxford University, UK), Carrie Smiley, R.N., Tatiana Foroud, Ph.D., Leah Flury, M.S., Danielle M.Dick, Ph.D (at Virginia Commonwealth University), Howard Edenberg, Ph.D.; Washington University, St. Louis, MO, R01 MH059534, John Rice, Ph.D, Theodore Reich, M.D., Allison Goate, Ph.D., Laura Bierut, M.D.K02 DA21237; Johns Hopkins University, Baltimore, M.D., R01 MH59533, Melvin McInnis, M.D., J.Raymond DePaulo, Jr., M.D., Dean F. MacKinnon, M.D., Francis M. Mondimore, M.D., James B. Potash, M.D., Peter P. Zandi, Ph.D, Dimitrios Avramopoulos, and Jennifer Payne; University of Pennsylvania, PA, R01 MH59553, Wade Berrettini, M.D., Ph.D.; University of California at San Francisco, CA, R01 MH60068, William Byerley, M.D., and Sophia Vinogradov, M.D.; University of Iowa, IA, R01 MH059548, William Coryell, M.D., and Raymond Crowe, M.D.; University of Chicago, IL, R01 MH59535, Elliot Gershon, M.D., Judith Badner, Ph.D., Francis McMahon, M.D., Chunyu Liu, Ph.D., Alan Sanders, M.D., Maria Caserta, Steven Dinwiddie, M.D., Tu Nguyen, Donna Harakal; University of California at San Diego, CA, R01 MH59567, John Kelsoe, M.D., Rebecca McKinney, B.A.; Rush University, IL, R01 MH059556, William Scheftner, M.D., Howard M. Kravitz, D.O., M.P.H., Diana Marta, B.S., Annette Vaughn-Brown, M.S.N., R.N., and Laurie Bederow, M.A.; NIMH Intramural Research Program, Bethesda, MD, 1Z01MH002810-01, Francis J. McMahon, M.D., Layla Kassem, Psy.D., Sevilla Detera-Wadleigh, Ph.D, Lisa Austin, Ph.D, Dennis L. Murphy, M.D.; Howard University, William B. Lawson, M.D., Ph.D., Evarista Nwulia, M.D., and Maria Hipolito, M.D. This work was supported by the NIH grants P50CA89392 from the National Cancer Institute and 5K02DA021237 from the National Institute of Drug Abuse. The Canadian part of the study was supported by the Canadian Institutes of Health Research grant (#166098), as well as Genome Canada and Research Nova Scotia grants to MA. Collection and phenotyping of the Australian UNSW sample, by Philip B. Mitchell, Peter R. Schofield, Janice M. Fullerton and Adam Wright, was funded by an Australian NHMRC Program Grant (No.1037196). The collection of the Barcelona sample was supported by the Centro de Investigación en Red de Salud Mental (CIBERSAM), IDIBAPS, and the CERCA Programme / Generalitat de Catalunya (grant numbers PI080247, PI1200906, PI12/00018, 2014SGR1636, and 2014SGR398). The Swedish Research Council, the Stockholm County Council, Karolinska Institutet and the Söderström-Königska Foundation supported this research through grants awarded to Lena Backlund, Louise Frise’n, Catharina Lavebratt and Martin Schalling. The collection of the Geneva sample was supported by the Swiss National Foundation (grants Synapsy 51NF40-158776 and 32003B-125469). The collection of the Romanian sample was supported by U.E.F.I.S.C.D.I., Romania, grant awarded to Maria Grigoroiu-Serbanescu. Open Access funding enabled and organized by CAUL and its Member Institutions.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Safety intervention for improving functioning in suicidal attempters (STRONG): A secondary prevention study. Study rationale and research protocol

  • Roberto, Natalia
  • Toll Privat, Alba
  • Elices, Matilde
  • Pérez Solá, Victor
  • Grande, Iria
Data de publicació electrònica: 07-09-2023, Background: Suicide is one of the most largely preventable causes of death worldwide. The aim of the STRONG study is to assess the effectiveness of a specific intervention (an extended Safety Planning Intervention) called iFightDepression-SURVIVE (iFD-S) in suicidal attempters by changes in psychosocial functioning. As secondary outcomes, quality of life, cognitive performance, clinical state and neuroimaging correlates will be considered. Objective: To describe the rationale and design of the STRONG study, an extension of the SURVIVE study, a national multicenter cohort about on prevention in suicidal attempters. Methods: The STRONG study is a two-year clinical trial. A total sample of 60 patients will be randomly allocated to two arms: a group will receive a iFD-S and treatment as usual (TAU) (n=30 treatment group), while another group will exclusively receive TAU (n=30 control group). There will be three study points: baseline; 3-month; and 6-month follow-up assessments, all of which will include rater-blinded evaluation of psychosocial functioning, quality of life, clinical state, cognitive performance and neuroimaging acquisition. Results: It is expected to obtain data on the efficacy of iFD-S in patients who have committed a suicide attempt. Conclusion: Results will provide insight into the effectiveness of IFD-S in suicidal attempters with respect to improvements in psychosocial functioning, quality of life, cognition, and neuroimaging correlates. Clinical trials id: NCT05655390., EV wishes to acknowledge the support from CIBER – Consorcio Centro de Investigación Biomédica en Red – (CB07/09/0004), Instituto de Salud Carlos III, the Spanish Ministry of Science and Innovation (PI18/00805, PI21/00787), Instituto de Salud Carlos III – Fondo Europeo de Desarrollo Regional (FEDER). Unión Europea. “Una manera de hacer Europa”, cofinanciado por la Unión Europea; the CERCA Program/Generalitat de Catalunya and Secretaria d’Universitats i Recerca del Departament d’Economia I Coneixement (2021 SGR 01358). Departament de Salut de la Generalitat de Catalunya, Pla Estratègic de Recerca i Innovació en Salut (PERIS) 2016-2020 (SLT006/17/00357). Thanks are also given for the support received from the European Union Horizon 2020 research and innovation program (EU.3.1.1. Understanding health, wellbeing and disease: grant no. 754907 and EU.3.1.3. Treating and managing disease: grant no. 945151). ME has a Juan de la Cierva research contract awarded by the ISCIII (FJCI-2017-31738). VP, ME, and AT want to thank unrestricted research funding from “Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement” (2017 SGR 134 to “Mental Health Research Group”), Generalitat de Catalunya (Government of Catalonia). PAS has received partial support from the Government of the Principality of Asturias PCTI-2021-2023 IDI/2021/111, the Fundación para la Investigación e Innovación Biosanitaria del Principado de Asturias (FINBA), and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, and Ministerio de Ciencia e Innovación. The funders had no role in the study design, decision to publish, or preparation of the manuscript.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Association of polygenic score and the involvement of cholinergic and glutamatergic pathways with lithium treatment response in patients with bipolar disorder

  • Amare, Azmeraw T.
  • Colom, Francesc
  • Baune, Bernhard T.
Lithium is regarded as the first-line treatment for bipolar disorder (BD), a severe and disabling mental health disorder that affects about 1% of the population worldwide. Nevertheless, lithium is not consistently effective, with only 30% of patients showing a favorable response to treatment. To provide personalized treatment options for bipolar patients, it is essential to identify prediction biomarkers such as polygenic scores. In this study, we developed a polygenic score for lithium treatment response (Li+PGS) in patients with BD. To gain further insights into lithium's possible molecular mechanism of action, we performed a genome-wide gene-based analysis. Using polygenic score modeling, via methods incorporating Bayesian regression and continuous shrinkage priors, Li+PGS was developed in the International Consortium of Lithium Genetics cohort (ConLi+Gen: N = 2367) and replicated in the combined PsyCourse (N = 89) and BipoLife (N = 102) studies. The associations of Li+PGS and lithium treatment response - defined in a continuous ALDA scale and a categorical outcome (good response vs. poor response) were tested using regression models, each adjusted for the covariates: age, sex, and the first four genetic principal components. Statistical significance was determined at P < 0.05. Li+PGS was positively associated with lithium treatment response in the ConLi+Gen cohort, in both the categorical (P = 9.8 × 10-12, R2 = 1.9%) and continuous (P = 6.4 × 10-9, R2 = 2.6%) outcomes. Compared to bipolar patients in the 1st decile of the risk distribution, individuals in the 10th decile had 3.47-fold (95%CI: 2.22-5.47) higher odds of responding favorably to lithium. The results were replicated in the independent cohorts for the categorical treatment outcome (P = 3.9 × 10-4, R2 = 0.9%), but not for the continuous outcome (P = 0.13). Gene-based analyses revealed 36 candidate genes that are enriched in biological pathways controlled by glutamate and acetylcholine. Li+PGS may be useful in the development of pharmacogenomic testing strategies by enabling a classification of bipolar patients according to their response to treatment., AT Amare received the 2019–2021 National Alliance for Research on Schizophrenia and Depression (NARSAD) Young Investigator Grant from the Brain & Behaviour Research Foundation (BBRF) and is currently supported by National Health and Medical Research Council (NHMRC) Emerging Leadership (EL1) Investigator Grant (APP2008000). The primary sources of funding were the Deutsche Forschungsgemeinschaft (DFG; grant no.RI 908/7-1; grant FOR2107, RI 908/11-1 to Marcella Rietschel, NO 246/10-1 to Markus M. Nöthen) and the Intramural Research Program of the National Institute of Mental Health (ZIA-MH00284311; ClinicalTrials.gov identifier: NCT00001174). The genotyping was in part funded by the German Federal Ministry of Education and Research (BMBF) through the Integrated Network IntegraMent (Integrated Understanding of Causes and Mechanisms in Mental Disorders), under the auspices of the e:Med Programme (grants awarded to Thomas G. Schulze, Marcella Rietschel, and Markus M. Nöthen). Improving Recognition and Care in Critical Areas of Bipolar Disorders (BipoLife) study was funded by Bundesministerium für Bildung und Forschung (BMBF): PIs – Felix Bermpohl, Philipp Ritter, Michael Bauer, Andreas Reif, Sarah Kittel-Schneider, Thomas G. Schulze, Jens Wiltfang, Georg Juckel, Andreas Fallgatter and Martin Lambert. Urs Heilbronner was supported by European Union’s Horizon 2020 Research and Innovation Programme (PSY-PGx, grant agreement No 945151). Some data and biomaterials were collected as part of eleven projects (Study 40) that participated in the National Institute of Mental Health (NIMH) Bipolar Disorder Genetics Initiative. From 2003–2007, the Principal Investigators and Co-Investigators were: Indiana University, Indianapolis, IN, R01 MH59545, John Nurnberger, M.D., Ph.D., Marvin J. Miller, M.D., Elizabeth S. Bowman, M.D., N. Leela Rau, M.D., P.Ryan Moe, M.D., Nalini Samavedy, M.D., Rif El-Mallakh, M.D. (at University of Louisville), Husseini Manji, M.D.(at Johnson and Johnson), Debra A.Glitz, M.D.(at Wayne State University), Eric T.Meyer, Ph.D., M.S.(at Oxford University, UK), Carrie Smiley, R.N., Tatiana Foroud, Ph.D., Leah Flury, M.S., Danielle M.Dick, Ph.D (at Virginia Commonwealth University), Howard Edenberg, Ph.D.; Washington University, St. Louis, MO, R01 MH059534, John Rice, Ph.D, Theodore Reich, M.D., Allison Goate, Ph.D., Laura Bierut, M.D.K02 DA21237; Johns Hopkins University, Baltimore, M.D., R01 MH59533, Melvin McInnis, M.D., J.Raymond DePaulo, Jr., M.D., Dean F. MacKinnon, M.D., Francis M. Mondimore, M.D., James B. Potash, M.D., Peter P. Zandi, Ph.D, Dimitrios Avramopoulos, and Jennifer Payne; University of Pennsylvania, PA, R01 MH59553, Wade Berrettini, M.D., Ph.D.; University of California at San Francisco, CA, R01 MH60068, William Byerley, M.D., and Sophia Vinogradov, M.D.; University of Iowa, IA, R01 MH059548, William Coryell, M.D., and Raymond Crowe, M.D.; University of Chicago, IL, R01 MH59535, Elliot Gershon, M.D., Judith Badner, Ph.D., Francis McMahon, M.D., Chunyu Liu, Ph.D., Alan Sanders, M.D., Maria Caserta, Steven Dinwiddie, M.D., Tu Nguyen, Donna Harakal; University of California at San Diego, CA, R01 MH59567, John Kelsoe, M.D., Rebecca McKinney, B.A.; Rush University, IL, R01 MH059556, William Scheftner, M.D., Howard M. Kravitz, D.O., M.P.H., Diana Marta, B.S., Annette Vaughn-Brown, M.S.N., R.N., and Laurie Bederow, M.A.; NIMH Intramural Research Program, Bethesda, MD, 1Z01MH002810-01, Francis J. McMahon, M.D., Layla Kassem, Psy.D., Sevilla Detera-Wadleigh, Ph.D, Lisa Austin, Ph.D, Dennis L. Murphy, M.D.; Howard University, William B. Lawson, M.D., Ph.D., Evarista Nwulia, M.D., and Maria Hipolito, M.D. This work was supported by the NIH grants P50CA89392 from the National Cancer Institute and 5K02DA021237 from the National Institute of Drug Abuse. The Canadian part of the study was supported by the Canadian Institutes of Health Research grant (#166098), as well as Genome Canada and Research Nova Scotia grants to MA. Collection and phenotyping of the Australian UNSW sample, by Philip B. Mitchell, Peter R. Schofield, Janice M. Fullerton and Adam Wright, was funded by an Australian NHMRC Program Grant (No.1037196). The collection of the Barcelona sample was supported by the Centro de Investigación en Red de Salud Mental (CIBERSAM), IDIBAPS, and the CERCA Programme / Generalitat de Catalunya (grant numbers PI080247, PI1200906, PI12/00018, 2014SGR1636, and 2014SGR398). The Swedish Research Council, the Stockholm County Council, Karolinska Institutet and the Söderström-Königska Foundation supported this research through grants awarded to Lena Backlund, Louise Frise’n, Catharina Lavebratt and Martin Schalling. The collection of the Geneva sample was supported by the Swiss National Foundation (grants Synapsy 51NF40-158776 and 32003B-125469). The collection of the Romanian sample was supported by U.E.F.I.S.C.D.I., Romania, grant awarded to Maria Grigoroiu-Serbanescu. Open Access funding enabled and organized by CAUL and its Member Institutions.
RUO. Repositorio Institucional de la Universidad de Oviedo
Publication Artículo científico (JournalArticle)

Lithium response in bipolar disorder: epigenome-wide dna methylation signatures and epigenetic aging

  • Zafrilla López, M.
  • Acosta Díez, M.
  • Mitjans, M.
  • Saiz Martínez, Pilar Alejandra
  • García-Portilla González, María Paz|||0000-0003-3643-1622
  • González Blanco, Leticia|||0000-0001-6238-4773
  • Bobes, Julio|||0000-0003-2187-4033
This work was supported by the Institute of Health Carlos III through projects PI16/00998, PI17/01122, PI18/00805, PI21/00787, PI22/01048 and PI22/00431 co-funded by European Regional Development Fund (ERDF)/European Social Fund “Investing in your future”, (...) the Spanish ‘Ministerio de Ciencia, Innovaci´ on y Universidades’ (PID2021–1277760B-I00, PID2022–139740OA-I00) (...) MM, SP, BA, AB, AGP, EJ, AB, PAS, PGP, LGB and JB, thanks the support by CIBER -Consorcio Centro de Investigación Biomédica en Red, Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation (CB07/09/0037, CB07/09/0004 and CB07/09/0020). MM was supported by Horizon 2020 Marie Sklodowska-Curie Individual Fellowship from the European Commission under grant agreement no. 841899 (GRASAD). This article is part of the grant RYC2021–033573-I funded by MICIU/AEI/10.13039/501100011033 and by the European Union NextGenerationEU/PRTR. AGP receives financial support from an educational grant from the Spanish Ministry of Health, Instituto de Salud Carlos III (CM21/00094) and by the European Social Fund Plus (FSE+). EV (...) support of the European Union Horizon 2020 research and innovation program (EU.3.1.1. Understanding health, wellbeing, and disease: Grant No 754907 and EU.3.1.3. Treating and managing disease: Grant No 945151)., Zafrilla-López M., Acosta-Díez M., Mitjans M., Giménez-Palomo A., Saiz P.A., Barrot-Feixat C., Jiménez E., Papiol S., Ruiz V., Gavín P., García-Portilla M.P., González-Blanco L., Bobes J., Schulze T.G., Vieta E., Benabarre A., Arias B.
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publication Artículo científico (JournalArticle)

Interrelationships between polygenic risk scores, cognition, symptoms, and functioning in first-episode psychosis: a network analysis approach

  • Gil Berrozpe, Gustavo José
  • Segura, Àlex G.
  • Sánchez Torres, Ana María
  • Amoretti, Silvia
  • Giné-Servén, Eloi
  • Vieta, Eduard
  • Mezquida, Gisela
  • Lobo, Antonio
  • González Pinto, Ana
  • Andreu-Bernabeu, Álvaro
  • Roldán, Alexandra
  • Forte, María Florencia
  • Castro, Josefina
  • Bergé, Daniel
  • Rodríguez, Natalia
  • Ballesteros, Alejandro
  • Mas, Sergi
  • Cuesta, Manuel J.
  • Bernardo, Miguel
  • PEPs Group
Psychopathological manifestations and cognitive impairments are core features of psychotic disorders. Polygenic risk scores (PRS) offer insights into the relationships between genetic vulnerability, symptomatology, and cognitive impairments. This study used a network analysis to explore the connections between PRS, cognition, psychopathology, and overall functional outcomes in individuals experiencing a first episode of psychosis (FEP). The study sample comprised 132 patients with FEP. Genetic data were used to construct PRS for mental disorders and cognitive traits via PRS-continuous shrinkage. We conducted comprehensive clinical and neuropsychological assessments at 2 months post-diagnosis and again at a 2-year follow-up. A network analysis was performed to generate two distinct networks and their centrality indices, encompassing 19 variables across domains such as symptoms, cognition, functioning, and PRS. Variables were grouped within related domains, and stronger relationships were observed within domains than between them. PRS for schizophrenia showed weak negative associations with attention, working memory, and verbal memory, while PRS for cognitive performance showed weak positive associations with attention. Negative symptoms were negatively associated with functioning and verbal memory at both the 2-month and 2-year assessments, as well as with social cognition at 2 years. Poor functioning was moderately related to greater severity of Positive and Negative Syndrome Scale dimensions. This study identified pathways linking PRS, cognition, symptoms, and functioning, suggesting that genetic risk may serve as a marker of vulnerability and disorder progression. The findings also highlight the importance of considering genetic predispositions alongside clinical and cognitive factors to better understand the heterogeneity of psychotic disorders., EV thanks the support of the Spanish Ministry of Science and Innovation (PI21/00787) integrated into the Plan Nacional de I + D + I and co-financed by the Instituto de Salud Carlos III -Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER); the Secretaria d'Universitats i Recerca del Departament d'Economia i Coneixement (2021-SGR-01358), CERCA Programme, Generalitat de Catalunya; La Marató-TV3 Foundation grants 202234-30; the European Union Horizon 2020 research and innovation program (H2020-EU.3.1.1. - Understanding health, wellbeing and disease, H2020-EU.3.1.3. Treating and managing disease: Grant 945151, HORIZON.2.1.1 - Health throughout the Life Course: Grant 101057454 and EIT Health (EDIT-B project).